Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The role of in vitro directed chemotherapy in epithelial ovarian cancer.

Literature DB >> 20842282

The role of in vitro directed chemotherapy in epithelial ovarian cancer.

Abstract

Epithelial ovarian cancer (EOC) continues to be the most lethal gynecologic malignancy. Efforts to personalize chemotherapy treatments by utilizing in vitro tumor assays to predict chemotherapeutic response have been tested in both the primary and recurrent treatment setting. To date, several retrospective studies have suggested improved response rates to predicted chemotherapeutic agents. However, a prospective, controlled trial merely found equivalence between in vitro prediction and empirical treatment selection. This review summarizes the current data regarding in vitro directed chemotherapy in EOC.

Entities: Disease

Keywords: Chemotherapy resistance assay; Chemotherapy sensitivity assay; Epithelial ovarian cancer

Year: 2010 PMID： 20842282 PMCID： PMC2938901

Source DB: PubMed Journal: Rev Obstet Gynecol ISSN： 1941-2797

24 in total

1. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors: Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245

Review 2. In vitro drug resistance versus chemosensitivity: two sides of different coins.

Authors: John P Fruehauf; David S Alberts
Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544

3. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.

Authors: D H Kern; L M Weisenthal
Journal: J Natl Cancer Inst Date: 1990-04-04 Impact factor: 13.506

4. Chemosensitivity testing predicts survival in ovarian cancer.

Authors: C G Taylor; J M Sargent; A W Elgie; C J Williamson; G M Lewandowicz; O Chappatte; J G Hill
Journal: Eur J Gynaecol Oncol Date: 2001 Impact factor: 0.196

5. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

Authors: A N Gordon; J T Fleagle; D Guthrie; D E Parkin; M E Gore; A J Lacave
Journal: J Clin Oncol Date: 2001-07-15 Impact factor: 44.544

6. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy.

Authors: Vera Loizzi; John K Chan; Kathryn Osann; Fabio Cappuccini; Philip J DiSaia; Michael L Berman
Journal: Am J Obstet Gynecol Date: 2003-11 Impact factor: 8.661

7. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.

Authors: Deborah Schrag; Harinder S Garewal; Harold J Burstein; David J Samson; Daniel D Von Hoff; Mark R Somerfield
Journal: J Clin Oncol Date: 2004-08-02 Impact factor: 44.544

8. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery.

Authors: Jae K Lee; Dmytro M Havaleshko; Hyungjun Cho; John N Weinstein; Eric P Kaldjian; John Karpovich; Andrew Grimshaw; Dan Theodorescu
Journal: Proc Natl Acad Sci U S A Date: 2007-07-31 Impact factor: 11.205

9. Cancer statistics, 2009.

Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal: CA Cancer J Clin Date: 2009-05-27 Impact factor: 508.702

10. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Authors: David G Mutch; Mauro Orlando; Tiana Goss; Michael G Teneriello; Alan N Gordon; Scott D McMeekin; Yanping Wang; Dennis R Scribner; Martin Marciniack; R Wendel Naumann; Angeles Alvarez Secord
Journal: J Clin Oncol Date: 2007-07-01 Impact factor: 44.544

3 in total

Review 1. Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.

Authors: Molly M Morgan; Brian P Johnson; Megan K Livingston; Linda A Schuler; Elaine T Alarid; Kyung E Sung; David J Beebe
Journal: Pharmacol Ther Date: 2016-05-21 Impact factor: 12.310

Review 2. Episensitization: Defying Time's Arrow.

Authors: Bryan T Oronsky; Arnold L Oronsky; Michelle Lybeck; Neil C Oronsky; Jan J Scicinski; Corey Carter; Regina M Day; Jose F Rodriguez Orengo; Maribel Rodriguez-Torres; Gary F Fanger; Tony R Reid
Journal: Front Oncol Date: 2015-06-11 Impact factor: 6.244

3. Biological Insights into Chemotherapy Resistance in Ovarian Cancer.

Authors: Michelle A Glasgow; Peter Argenta; Juan E Abrahante; Mihir Shetty; Shobhana Talukdar; Paula A Croonquist; Mahmoud A Khalifa; Timothy K Starr
Journal: Int J Mol Sci Date: 2019-04-30 Impact factor: 5.923

3 in total